Increased Severity of Ulcerative Colitis in the Terminal Phase of the Metabolic Syndrome

Једноставна страница ставке
dc.citation.epage182
dc.citation.spage171
dc.citation.volume254
dc.contributor.authorJovanovic, Marina Milun
dc.contributor.authorJurisevic, Milena Milenko
dc.contributor.authorGajovic, Nevena Miroslav
dc.contributor.authorArsenijevic, Nebojsa Nikola
dc.contributor.authorJocic, Miodrag Vukasin
dc.contributor.authorJovanovic, Ivan Petar
dc.contributor.authorZdravkovic, Natasa Dragan
dc.contributor.authorDjukic, Aleksandar Ljubodrag
dc.contributor.authorMaric, Veljko Jovo
dc.contributor.authorJovanovic, Milan Milorad
dc.date.accessioned2023-06-06T09:35:17Z
dc.date.available2023-06-06T09:35:17Z
dc.date.issued2021
dc.description.abstractUlcerative colitis is chronic immune-mediated disorder that affects primarily colonic mucosa. The metabolic syndrome has increasing global prevalence with a significant impact on biology of chronic diseases, such as ulcerative colitis. Today it is known that the metabolic syndrome attenuates severity of ulcerative colitis. Still, there is no evidence that different stages of metabolic syndrome alter the course of the ulcerative colitis. The aim of this study was to dissect out how progression of the metabolic syndrome impacted the biology of ulcerative colitis and severity of clinical presentation. Seventy-two patients (41 men and 31 women, 22-81 years old) were enrolled in this observational cross-sectional study. Concentrations of proand anti-inflammatory cytokines in serum and feces samples were measured and phenotype of colon infiltrating cells was analyzed. Patients in the terminal phase of the metabolic syndrome have clinically and pathohistologically more severe form of ulcerative colitis, which is followed by decreased concentrations of systemic galectin-1, increased values of systemic pro-inflammatory mediators and increased influx of lymphocytes in affected colon tissue. Our data suggest that reduced concentrations of galectin-1 and predomination of the pro-inflammatory mediators in patients with terminal stage of the metabolic syndrome enhance local chronic inflammatory response and subsequent tissue damage, and together point on important role of galectin-1 in immune response in ulcerative colitis patients with the metabolic syndrome.
dc.identifier.doi10.1620/tjem.254.171
dc.identifier.urihttps://vaseljena.ues.rs.ba/handle/123456789/282
dc.language.isoen
dc.sourceThe Tohoku Journal of Experimental Medicine
dc.subjectdisease severity; immune response; metabolic syndrome progression; ulcerative colitis
dc.titleIncreased Severity of Ulcerative Colitis in the Terminal Phase of the Metabolic Syndrome
dc.typeArticle
Датотеке
Оригинални завежљај
Сада се приказује 1 - 1 од 1
Сличица
Име:
Increased Severity of Ulcerative Colitis in the Terminal Phase of.pdf
Величина:
1.17 MB
Формат:
Adobe Portable Document Format
Опис:
Преузимање
Свежањ лиценце
Сада се приказује 1 - 1 од 1
Сличица
Име:
license.txt
Величина:
1.71 KB
Формат:
Item-specific license agreed to upon submission
Опис:
Преузимање
Колекције
Медицински факултет [Научни радови] / Faculty of Medicine [Scientific papers]